Cognitive & NeuroprotectivePreclinical / anecdotal

Angiotensin IV analog (Nle1-AngIV derived)

Dihexa, Procognitive synaptogenic compound

An angiotensin IV analog reported in preclinical models to be a potent procognitive/synaptogenic compound acting via HGF/c-Met signaling.

Cognition Neuroprotection

Ang IV

Derived from

HGF / c-Met

Pathway

Human trials

Mechanism of action

How Dihexa works

An angiotensin IV derivative engineered for the brain, reported in preclinical models to drive synapse formation via HGF/c-Met. Entirely preclinical, with no human data.

Dihexa

Ang IV analog

HGF / c-Met

Potentiation

Synaptogenesis

Hippocampal

Cognition

Preclinical

Also studied

Reported to potentiate HGF at its c-Met receptor, driving synapse formation in hippocampal models, preclinical assays, not clinical outcomes.

See related compounds

Touted for Alzheimer's and cognition, but no human trials exist for any endpoint.

See related compounds

Potent c-Met activation raises a theoretical cancer concern, and a key supporting paper has since been retracted; human safety is unknown.

Applications

Research applications

Cognition / synaptogenesis

Preclinical

Animal (rodent) model

Hippocampal models

Alzheimer's

Neuroprotection

In vitro / cell model

No human trials

Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.

Compound data

Molecular profile

CAS number1401708-83-5

Molecular formulaC27H44N4O5

Molecular weight504.66 g/mol

TypeAngiotensin IV derived oligopeptide

AppearanceWhite powder

Full profile

Evidence, safety & status

Claimed benefits & evidence

Preclinical only; touted for Alzheimer's/cognition. No human trials, the 'potent synaptogenesis' claims are from preclinical assays, not clinical outcomes.

Safety & dangers

Potent synaptogenesis/HGF-c-Met activation raises a theoretical oncogenic concern (c-Met is an oncogene); human safety unknown.

Regulatory status

Not FDA approved; Category 2 (2023), removed April 2026; slated for a later PCAC meeting (by Feb 2027). WADA: S0.

Administration

Oral/topical/subcutaneous (research).

Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. Anyone considering these compounds should consult a qualified physician.

For research use only

For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.